| Document |
Document Title |
|
WO/2022/000087A1 |
It is provided the synthesis of an aptamer-like encoded oligomer (ALEnOmer), method of producing same and method of preparing a library of ALEnOmes. More particularly, the method of preparing ALEnOmer comprises coupling at least one phos...
|
|
WO/2022/006231A1 |
Provided herein are compounds and methods of using these compounds to treat disorders related to DPAGT1 function, including cancer and bacterial infections.
|
|
WO/2021/261062A1 |
Provided is an aqueous solution having, dissolved therein, 0.3 to 200 mM of a stilbene compound (A) that is a compound represented by formula (1) or a glycoside thereof and 0.3 to 200 mM of a flavin derivative (B) selected from riboflavi...
|
|
WO/2021/260107A1 |
This specification discloses a novel methodology for labelling RNA via enzymatic incorporation of a minimally perturbing fluorescent tricyclic cytosine analogue. This analogue is shown to be 100% incorporated in example transcripts and i...
|
|
WO/2021/259881A1 |
The present invention concerns a nucleoside or nucleotide comprising a nucleobase attached to a detectable label via a cleavable linker, wherein the nucleoside or nucleotide comprises a ribose or 2' deoxyribose moiety and a 3'-OH blockin...
|
|
WO/2021/262786A1 |
The disclosure relates, in certain aspects, to the discovery of certain compounds that are useful to treat and/or prevent fungal infections in a subject. The disclosure further relates, in certain aspects, to the discovery of certain com...
|
|
WO/2021/253362A1 |
A method for preparing nicotinamide mononucleotide by using nicotinamide as a raw material, the method comprising: in a solvent of acetonitrile, dichloromethane, 1,2-dichloroethane or a liquid sulfur dioxide, catalyzing the reaction of n...
|
|
WO/2021/257569A1 |
The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an "NMN-like" moiety linked to another moiety with biological activity upon adm...
|
|
WO/2021/256297A1 |
[Problem] To provide: a bridged nucleoside which is not likely to be degraded by nuclease in vivo, while having high binding affinity and specificity to target mRNA and being capable of efficiently controlling the expression of a specifi...
|
|
WO/2021/257643A1 |
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The ...
|
|
WO/2021/250443A1 |
The present application relates to spreadable, margarine-type products with a fat content of between 58% and 70%, which use natural flavouring techniques together with crystallisation processes to reduce the sodium content by between 40%...
|
|
WO/2021/236208A1 |
Provided is a method of treating a disease caused by a nidovirus that encodes Nsp15, such as a coronavirus, an arterivirus, or a torovirus, in a subject in need thereof comprising administering a therapeutically effective amount of an ac...
|
|
WO/2021/232719A1 |
A conjugate containing an α-galactosyl ceramide analogue and a carbohydrate antigen and a preparation method therefor and a use thereof, belonging to the technical field of antitumor carbohydrate vaccine development. Provided is the con...
|
|
WO/2021/234532A1 |
The present invention relates to a pharmaceutical formulation of 5-fluoropyrimidine derivatives or a salt, solvate, or hydrate thereof for oral administration wherein the formulation is a simple composition for ingestion, simple, safest,...
|
|
WO/2021/231324A1 |
Many regions of genomic DNA are highly similar to other regions of the genome and thus are very difficult to capture without also capturing the similar, undesired regions. This leads to over-sequencing of regions for which there is no in...
|
|
WO/2021/226521A1 |
Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or su...
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/223398A1 |
Provided in the present invention is a crystal form for treating a liver disease of tenofovir phosphate(9-[(2R)-2-[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2-
dioxaphosphorinane-2-methoxy]propyl]adenine fumarate), paladovir mesylate((+)-cis-...
|
|
WO/2021/226327A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.
|
|
WO/2021/217685A1 |
A six-membered ring-containing nucleoside compound 7 and a preparation method therefor. The structural formula of the compound 7 is (I), wherein R1 is selected from one of (II), (III), (IV), and (V), and R2 is hydroxyl or alkynyl.
|
|
WO/2021/216998A1 |
Disclosed herein, inter alia, are compounds, modified nucleotides, compositions, and methods of using the same.
|
|
WO/2021/216722A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/216940A1 |
A method of producing a triazoline-containing compound, the method comprising reacting an alkene, which comprises at least one a C=C double bond, with an azido compound, which comprises an azide anion having the chemical formula N3 -, wh...
|
|
WO/2021/214299A1 |
The present invention relates to Nicotinamide mononucleotide derivatives of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present invention further relates to phar...
|
|
WO/2021/211890A1 |
In one aspect, the disclosure relates to pharmaceutical compositions comprising 2'-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates t...
|
|
WO/2021/211759A1 |
Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop- gap methods for controlling the spread of Poxviridae virus i...
|
|
WO/2021/203409A1 |
A novel non-hygroscopic low-variability crystalline form for treatment of hepatitis C. The novel crystalline form T has a simple crystallization process, is easy for industrial production, and has no hygroscopicity. The use of a suitable...
|
|
WO/2021/196105A1 |
The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a ...
|
|
WO/2021/202907A2 |
The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remd...
|
|
WO/2021/202788A2 |
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard 4' -thio nucleoside.
|
|
WO/2021/198958A1 |
A nucleic acid polymer comprising 8 to 50 nucleoside subunits linked by intersubunit linkages, wherein the nucleic acid polymer comprises (A) one or more 3'-5' thiophosphoramidate intersubunit linkage and the remaining intersubunit linka...
|
|
WO/2021/196349A1 |
An organic acid salt of nicotinamide riboside; the organic acid is selected from malic acid, citric acid, royal jelly acid, and so on, and the molar ratio of nicotinamide riboside to organic acid is 1:2 or 1:1. A compound composition of ...
|
|
WO/2021/198883A1 |
Methods of synthesizing oligonucleotides via new intermediates on a cleavable support having an azidomethyl moiety are disclosed. The method comprises multiple reaction cycles, each of which comprises sequential coupling a nucleoside or ...
|
|
WO/2021/198040A1 |
The invention relates to a method for preparing 3'-O-amino-2'-deoxyribonucleoside- 5'-triphosphates with reduced 3'-hydroxy-2'-deoxyribonucleoside-5'-triphosphate contamination by converting 3'-(N-acetone-oxime)-2'-deoxynucleoside tripho...
|
|
WO/2021/198725A1 |
The invention relates to fosalvudine and fozivudine tidoxil for use in the treatment of the coronavirus disease 2019 and to the use of the structurally simplified derivatives thereof for manufacturing a drug against Covid-19.
|
|
WO/2021/191830A1 |
The present invention relates to methods and intermediates for the synthesis of nucleosides and nucleoside analogues (NAs). More specifically, the present invention relates to methods of synthesizing nucleosides and NAs, using simple ach...
|
|
WO/2021/191333A1 |
The present invention relates to a compound library comprising a plurality of conjugate molecules, wherein said conjugates comprise a small organic molecule covalently coupled to a nucleic acid moiety, wherein the nucleic acid moiety com...
|
|
WO/2021/192683A1 |
A compound comprising β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, wherein the purity measured by HPLC is 95% or higher, and the reactivity to lactate dehydrogenase is 30 U or higher.
|
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
|
WO/2021/188959A1 |
The present disclosure provides prodrugs of 4'-C-substituted-2- halo-2'-deoxyadenoside nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating viral infections including, human immunodeficiency ...
|
|
WO/2021/186328A1 |
Provided herein are novel synthetic routes to amines through an oxime intermediate, e.g., 3'-N nucleosides and novel and intermediate compounds produced during these synthetic procedures.
|
|
WO/2021/173615A1 |
Functionalized solid supports are useful in the synthesis of oligonucleotides. The functionalized solid supports contain an extended linker to a terminal functional group or a first nucleotide or nucleoside moiety. The extended linker pe...
|
|
WO/2021/173713A1 |
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 vi...
|
|
WO/2021/167029A1 |
Disclosed is a bridged nucleoside and a nucleotide using the same. The nucleoside according to the present invention is represented by formula (I). The bridged nucleoside of the present invention is usable as a substitute for a phosphoro...
|
|
WO/2021/162725A1 |
A composition that is a fullerene covalently bonded to a phosphate of adenosine with a +5 phosphorus oxidation state. The fullerene can be C60 fullerene or C70 fullerene. A first fullerene can covalently bonded to one functional group of...
|
|
WO/2021/159044A1 |
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.
|
|
WO/2021/155477A1 |
This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low...
|
|
WO/2021/146488A1 |
The present invention relates to nucleic acids and analogues thereof useful as potent and stable RNA interference agents.
|
|
WO/2021/140471A1 |
A method of making nucleoside 1, which has a 3-hydrocarbyl-5-fluoro-5-(hydroxy-methyl)tetrahydrofuran-3,4
-diol ring system, where hydrocarbyl group R1 is lower alkyl, lower alkenyl, or lower alkynyl and R2 may be an adenine moiety havin...
|
|
WO/2021/137913A2 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
